Global private equity and venture capital news and research

AVG Ventures, Remeditex help cancer treatment company Bellicum to $34.4m Series B

8 Jan 2014

lab glass biotech pharma chemicalAVG Ventures and Remeditex Ventures have increased their backing of Bellicum Pharmaceuticals to help it raise $34.4m for its Series B round.

Bellicum said the funding would be used to expand clinical development of its leading cellular immunotherapy product candidates targeting leukaemia and prostate cancer.

Last October venture capital-backed biotech business Immune Design collected up to $49m in Series C financing as it continued to develop immune-based therapies for cancer and other chronic conditions.

The Column Group and new investor Topspin Partners led the round, which included an upfront investment of $32.5m.

Existing backers Alta Partners, Versant Ventures, Osage Venture Partners and ProQuest Investments also took part in the financing, while Sanofi-Genzyme BioVentures joined the syndicate as a new investor.

Copyright © 2014 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016